Jatenzo Pre-Surgery Hold Window: What Clinicians and Patients Need to Know

Why the Pre-Surgery Hold Window Exists

Testosterone therapy raises hematocrit, increases red-cell mass, and activates platelets through androgen-receptor-mediated pathways, all of which amplify venous thromboembolism (VTE) risk during and after surgery. Stopping Jatenzo before an operation gives the body time to normalize these parameters.

The Hematocrit Problem

Testosterone stimulates erythropoiesis by suppressing hepcidin and increasing erythropoietin sensitivity. A 2019 FDA safety communication confirmed that testosterone products carry a boxed warning for VTE, and that polycythemia is among the most clinically consequential adverse effects. Hematocrit rises gradually over 6 to 12 weeks of therapy, but its normalization after cessation is slower than simple drug clearance suggests.

In a 24-week open-label extension of the Jatenzo key study, Swerdloff et al. Reported that 15.8% of subjects developed hematocrit exceeding 54% at some point during treatment, prompting dose reductions or temporary holds. Full data are available via the published trial record at PubMed (PMID 31773132).

Platelet Activation and Coagulation Changes

Beyond erythrocytosis, testosterone modulates thromboxane A2 receptors on platelets and increases fibrinogen synthesis. A 2018 analysis published in the Journal of Clinical Endocrinology and Metabolism found that exogenous androgen administration was associated with a statistically significant increase in platelet aggregation at 12 weeks compared with baseline (PMID 29040528). These platelet-level changes persist for 3 to 5 weeks after the drug is stopped.

Why Jatenzo's Short Half-Life Does Not Solve the Problem

Jatenzo is absorbed via intestinal lymphatic transport, bypassing first-pass hepatic metabolism. Its terminal plasma half-life is approximately 8 to 10 hours, meaning serum testosterone returns to pre-dose levels within 24 to 48 hours of the last capsule. That fast clearance misleads some prescribers into thinking a 24 to 48-hour hold is sufficient. It is not. The downstream hematologic effects (elevated hematocrit, heightened platelet reactivity, and raised fibrinogen) persist on a weeks-long timescale that is entirely independent of drug plasma concentration. The FDA prescribing information for Jatenzo explicitly notes that hematocrit should be checked 3 to 6 months after initiation, implying the bone-marrow response to testosterone has its own biological clock.

Recommended Hold Duration by Procedure Type

No single randomized trial has tested Jatenzo-specific perioperative hold durations against a clinical endpoint. Current guidance is extrapolated from injectable and transdermal testosterone pharmacokinetics, VTE pathophysiology data, and Endocrine Society perioperative hormone guidelines.

Low VTE-Risk Procedures

Outpatient procedures under local anesthesia or with minimal tissue disruption (e.g., cataract removal, colonoscopy) carry VTE risk well below 0.5%. For these cases, many endocrinologists accept a 1 to 2 week hold, or no hold at all when hematocrit is below 50% at the most recent check within 30 days. The Endocrine Society's clinical practice guideline on testosterone therapy (2018 update) recommends maintaining hematocrit below 54% as a general safety threshold (Bhasin et al., J Clin Endocrinol Metab 2018, PMID 29750253).

Moderate VTE-Risk Procedures

Intra-abdominal, thoracic, orthopedic, and major urologic surgeries carry 1 to 3% baseline VTE risk. The consensus from perioperative medicine literature supports a 4-week minimum hold. A 2021 systematic review of androgen-related thrombotic events in surgical patients, published in Thrombosis Research, identified hematocrit above 52% and ongoing testosterone use as independent predictors of post-operative deep vein thrombosis (PMID 34058568).

High VTE-Risk Procedures

Hip and knee arthroplasty, prolonged neurosurgery, and major pelvic oncology resections carry VTE rates of 4 to 6% without prophylaxis. The recommended hold for these cases is 6 weeks, combined with pre-operative hematocrit confirmation below 50%. Some vascular surgery teams extend this to 8 weeks when the patient's baseline hematocrit was above 54% at any point during Jatenzo therapy.

Jatenzo Pharmacokinetics and Why They Matter Perioperatively

Lymphatic Absorption Pathway

Unlike older oral androgens such as methyltestosterone, Jatenzo delivers testosterone undecanoate dissolved in a castor-oil and polyoxylglycerides vehicle that promotes chylomicron incorporation. Drug reaches systemic circulation via the thoracic duct rather than the portal vein, which eliminates first-pass hepatic inactivation and avoids hepatotoxicity. The mechanism is confirmed in the FDA clinical pharmacology review archived at accessdata.fda.gov.

This lymphatic route means absorption is tightly food-dependent. Patients who skip a meal see a 50 to 75% reduction in Cmax. That food dependence does not change the hold-window decision, but it matters when assessing whether a patient's hematocrit truly reflects steady-state exposure or intermittent sub-therapeutic dosing.

Steady-State and Wash-Out Timeline

Steady-state serum testosterone is reached within 1 to 4 days of consistent twice-daily dosing. Wash-out of the parent drug and active metabolites (dihydrotestosterone and estradiol) is complete by 72 to 96 hours. The 2019 Swerdloff et al. Key trial, which enrolled 166 hypogonadal men and dosed them for 90 days, demonstrated that serum T fell below the eugonadal range within 48 hours of the last dose in virtually all participants (PMID 31773132).

Erythropoietic Lag Phase

Red blood cell lifespan is approximately 120 days. Once erythropoiesis is stimulated by testosterone, the resulting red-cell cohort circulates for up to 4 months. This lag between drug clearance and hematocrit normalization is the fundamental reason a 24 to 48-hour hold is physiologically inadequate. After testosterone withdrawal, hematocrit typically begins to decline within 2 to 3 weeks, but may not return to the patient's personal baseline for 6 to 8 weeks, particularly in men who had hematocrit above 52% at the time of the hold.

Anesthesia and Surgical Interactions

Blood Pressure and REMS Implications

Jatenzo carries a Risk Evaluation and Mitigation Strategy (REMS) specifically for its blood-pressure-raising effect. In the key Swerdloff trial, mean systolic blood pressure rose by 3.5 mmHg from baseline, and 20.8% of patients required a new or escalated antihypertensive prescription (PMID 31773132). Hypertension itself raises intraoperative risk. Anesthesiologists reviewing the medication list should note the REMS status, confirming that blood pressure was evaluated within 30 days before surgery. Full REMS requirements are posted at the FDA REMS database.

Fluid Retention and Hemodynamic Implications

Testosterone at supraphysiologic or even high-normal levels promotes sodium and water retention through aldosterone-pathway crosstalk. Perioperative fluid shifts are harder to predict in patients with testosterone-mediated volume expansion. Cardiac teams managing patients with reduced ejection fraction or known heart failure should coordinate with the prescribing endocrinologist at least 6 weeks ahead of a planned procedure.

Drug Interactions Relevant to Surgery

Testosterone is a mild inhibitor of CYP3A4-mediated metabolism. Drugs commonly used perioperatively that are CYP3A4 substrates include midazolam, fentanyl, and some volatile anesthetic agents. The interaction is pharmacokinetically modest, but a pre-operative medication reconciliation should note the combination. CYP3A4 interaction data for testosterone are catalogued in the NIH LiverTox database.

Pre-Operative Laboratory Checklist

Before any moderate-to-high VTE-risk procedure, the following labs should be obtained after Jatenzo has been held for at least 4 weeks.

Hematologic Parameters

• Complete blood count with differential: hematocrit target below 50% before proceeding
• Platelet count: testosterone can modestly raise platelet aggregability; confirm count is above 100,000/mcL
• Coagulation panel (PT, aPTT, INR): not routinely elevated by testosterone, but serves as baseline for anesthesia

Hormonal and Metabolic Parameters

• Serum total testosterone: confirms wash-out and establishes a pre-operative baseline for post-surgical restart dosing
• Estradiol: testosterone aromatizes to estradiol; elevated estradiol promotes coagulation factor synthesis
• Lipid panel: testosterone lowers HDL by 10 to 15% on average; relevant for cardiac risk stratification in procedures under general anesthesia per the 2019 AHA/ACC perioperative guideline, PMID 31104452
• Hemoglobin A1c: relevant if diabetes co-exists, given insulin sensitivity changes with testosterone therapy

Blood Pressure Confirmation

Given the REMS requirement, blood pressure should be measured at two separate visits within 30 days pre-operatively. Systolic above 160 mmHg warrants cardiology consultation before elective surgery proceeds. The American College of Cardiology recommends systolic below 180 mmHg as the threshold for proceeding with elective non-cardiac surgery (2024 ACC/AHA guideline update, PMID 38498661).

Post-Surgery Restart Protocol

Restarting Jatenzo too early risks anastomotic-site bleeding complications and adds thrombotic burden during the highest-risk post-operative window (days 1 to 14 post-surgery).

Standard Restart Timeline

For most elective procedures, restart at 2 to 4 weeks post-operatively, contingent on:

1. Confirmed hemostasis (no active wound bleeding, drain output below 30 mL/day)
2. Ambulation achieved (reduces VTE risk substantially)
3. Hematocrit below 50% on post-operative CBC
4. Blood pressure at or below the pre-operative baseline

Restart Dose Selection

Do not automatically restart at the pre-operative dose. The Swerdloff et al. Key data show that dose titration at 90 days produced the best benefit-to-risk ratio, with 87% of subjects achieving average serum T in the 300 to 1000 ng/dL range at the lowest effective dose (PMID 31773132). After a 4 to 8 week hold, restart at 158 mg twice daily and recheck serum T and hematocrit at 6 weeks.

Special Populations

Patients with a personal or family history of VTE, known thrombophilia (Factor V Leiden, prothrombin G20210A mutation), or active malignancy require hematology co-management before Jatenzo is restarted at any dose. The Endocrine Society guideline explicitly lists untreated or inadequately treated polycythemia and active VTE as absolute contraindications to testosterone therapy (Bhasin et al., J Clin Endocrinol Metab 2018, PMID 29750253).

Emergency Surgery: When There Is No Hold Window

Not every surgery can wait 4 to 6 weeks. For emergency or urgent procedures in a patient currently taking Jatenzo, the anesthesia team should receive three pieces of information from the prescribing clinician:

1. Current hematocrit (or most recent value)
2. Dose and duration of Jatenzo therapy (which predicts cumulative erythropoietic burden)
3. REMS blood pressure history

Intraoperatively, higher hematocrit increases blood viscosity, reduces microvascular perfusion, and elevates the risk of both DVT and arterial thrombosis. Regional anesthesia may be preferable to general anesthesia in high-hematocrit patients undergoing lower-extremity procedures, consistent with recommendations from the American Society of Anesthesiologists Task Force on Perioperative Blood Management (ASA guideline, PMID 25714945).

If the patient's hematocrit is above 52% at the time of emergency surgery, therapeutic phlebotomy to reduce hematocrit to below 50% before incision may be considered in consultation with hematology, provided volume status is adequately maintained. This approach is supported by data from polycythemia vera management guidelines published by the American Society of Hematology (Tefferi et al., Blood 2018, PMID 29895667).

Shared Decision-Making and Documentation

Prescribers carry documentation responsibility when a patient on Jatenzo is heading into surgery. The medical record should reflect:

• The date Jatenzo was stopped and the reason (pre-operative hold)
• The procedure type and planned date
• Pre-hold hematocrit, blood pressure, and serum testosterone
• The planned restart date and dose
• Communication sent to the surgical and anesthesia teams

A 2022 JAMA Internal Medicine analysis of perioperative adverse drug events found that incomplete pre-operative medication reconciliation was a contributing factor in 43% of preventable surgical complications (PMID 35404907). Testosterone products were among the hormone therapies most frequently omitted from pre-operative med lists.

Patients should receive written instructions specifying the exact last dose date. Oral testosterone is less visible to triage nurses than an injectable or transdermal product, and patients may not volunteer the information unless specifically prompted. As the 2018 Endocrine Society guideline states: "Clinicians should evaluate and monitor hematocrit before and during testosterone therapy to minimize the risk of polycythemia and associated cardiovascular complications" (Bhasin et al., PMID 29750253).

Jatenzo vs. Other Testosterone Formulations: Perioperative Differences

Injectable Testosterone Esters

Testosterone cypionate and enanthate have half-lives of 7 to 8 days and 4 to 5 days, respectively. Serum testosterone from a 200 mg IM injection of cypionate remains supraphysiologic for up to 14 days. The pre-surgery hold for injectables is typically 4 to 6 weeks from the last injection date, which is longer in calendar time but covers the same number of biologic half-lives as a Jatenzo hold. Pharmacokinetics for testosterone esters are summarized in the prescribing information maintained at accessdata.fda.gov.

Transdermal Testosterone

Gels and patches clear more rapidly than injectables but more slowly than Jatenzo on a per-dose basis. The same 4 to 6-week hematocrit normalization window applies. The key difference is that transdermal formulations at typical doses (50 to 100 mg/day gel) produce lower peak serum T and lower hematocrit elevation on average, so the absolute VTE risk is modestly lower.

Jatenzo's Unique BP Risk

The blood-pressure increase documented in the Swerdloff trial is more pronounced with Jatenzo than with transdermal formulations, likely because of the higher peak serum T values achieved postprandially. This makes Jatenzo the formulation with the most complex perioperative risk profile among the current FDA-approved oral options. A 2021 Endocrine Practice review of oral testosterone formulations confirmed that Jatenzo produced mean Cmax values approximately 20% higher than those achieved with equivalent dosing of transdermal testosterone.

Confirm hematocrit is below 50% and systolic blood pressure is below 160 mmHg at the pre-operative visit before clearing a Jatenzo patient for any procedure requiring general or neuraxial anesthesia.